JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2003; 42:81-87, doi:10.1016/S0735-1097(03)00498-4
© 2003 by the American College of Cardiology Foundation
This Article
Right arrow Abstract Freely available
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mitchell, L. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mitchell, L. B.

Are lipid-lowering drugs also antiarrhythmic drugs?

an analysis of the antiarrhythmics versus implantable defibrillators (AVID) trial

L. Brent Mitchell, MD, FACC*,*, Judy L. Powell, BSN{dagger}, Anne M. Gillis, MD, FACC*, Victoria Kehl, PhC{ddagger}, Alfred P. Hallstrom, PhD{dagger} the AVID Investigators

* Foothills Hospital/University of Calgary, Calgary, Alberta, Canada
{dagger} AVID Clinical Trial Center/University of Washington, Seattle, Washington, USA
{ddagger} Institut fuer Medizinische Statistik, Munich, Germany



View larger version (13K):

[in a new window]
 
Figure 1 Kaplan-Meier survival curves for the outcome of freedom from ventricular tachyarrhythmia recurrence in patients with an implantable cardioverter defibrillator as a function of whether lipid-lowering drug therapy was not used (dashed line, no LL Rx) or was used early and consistently (solid line, LL Rx). VT/VF = ventricular tachycardia/ventricular fibrillation.

 


View larger version (12K):

[in a new window]
 
Figure 2 Kaplan-Meier survival curves for the outcome of freedom from all-cause mortality as a function of whether lipid-lowering drug therapy was not used (dashed line, no LL Rx) or was used early and consistently (solid line, LL Rx).

 


View larger version (13K):

[in a new window]
 
Figure 3 Kaplan-Meier survival curves for the outcome of freedom from cardiac mortality as a function of whether lipid-lowering drug therapy was not used (dashed line, no LL Rx) or was used early and consistently (solid line, LL Rx).

 





HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2003 by the American College of Cardiology Foundation.